◎ Sugi Atlas

Atlas / Drug / Vorinostat

Vorinostat

drug
On this page

Also known as MK-0683MK0683NSC-701852NSC-748799NSC-759852Suberoylanilide hydroxamic acidZolinzasuberoylanilidehydroxamic acidSahaSuberoyl Anilide Hydroxamic AcidSID49645508SID104171411Suberoylanilide acidSID124893442SID144207172SID170465180SID144206158SID50113029Suberoylamide Hydroxamic Acid

Summary

Vorinostat (CHEMBL98) is an approved small-molecule EC 3.5.1.98 (histone deacetylase) inhibitor (ATC L01XH01) targeting HDAC10, HDAC11, and HDAC2; indicated across 96 conditions including primary cutaneous t-cell non-hodgkin lymphoma and neoplasm; with CIViC clinical evidence for 8 variant-indication associations (e.g. HDAC9 Overexpression in breast cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XH01
  • Targets: 9 (HDAC10, HDAC11, HDAC2…)
  • Indications: 96 conditions
  • Clinical trials: 256
  • Precision-oncology evidence (CIViC): 8 variant–indication associations
  • Chemistry: 264.32 Da · C14H20N2O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL98
NameVorinostat
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5311
ChEBICHEBI:45716
ATCL01XH01
Molecular formulaC14H20N2O3
Molecular weight264.32
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

IUPAC name: N’-hydroxy-N-phenyloctanediamide

ChEBI definition: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Pharmacological roles (ChEBI): EC 3.5.1.98 (histone deacetylase) inhibitor, apoptosis inducer, antineoplastic agent.

Also known as: MK-0683, MK0683, NSC-701852, NSC-748799, NSC-759852, Suberoylanilide hydroxamic acid, Vorinostat, Zolinza, suberoylanilide hydroxamic acid, suberoylanilidehydroxamic acid, vorinostat, Suberoylanilidehydroxamic acid

Patent coverage: 13,959 distinct patent families (50,361 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
HDAC10histone deacetylase 10Inhibition7.30%Q969S8
HDAC11histone deacetylase 11Inhibition7.440.2%Q96DB2
HDAC2histone deacetylase 2Inhibition8.83.1%Q92769
HDAC3histone deacetylase 3Inhibition8.395.1% (common-essential)O15379
HDAC6histone deacetylase 6Inhibition8.80%Q9UBN7
HDAC8histone deacetylase 8Inhibition6.694.9%Q9BY41
HDAC9histone deacetylase 9Inhibition7.190%Q9UKV0
HDAC1histone deacetylase 1Inhibition8.894.5%Q13547
HDAC5histone deacetylase 5Inhibition5.440.5%Q9UQL6

Broader ChEMBL bioactivity targets: 36 (assay-derived). Sample: Bromodomain-containing protein 4, Lysine-specific demethylase 4E, Nuclear receptor subfamily 0 group B member 1, Histone deacetylase 3, Protein deacetylase HDAC6, Histone deacetylase 2, Epidermal growth factor receptor, Histone deacetylase, Histone deacetylase, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2).

Bioactivity

ChEMBL activities: 1,952 potent at pChembl ≥ 5 of 2,036 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
HDAC29.75IC500.18nMCHEMBL_ACT_29210083
HDAC19.64IC500.23nMCHEMBL_ACT_26692241
HDAC39.46IC500.35nMCHEMBL_ACT_25701459
HDAC89.1IC500.79nMCHEMBL_ACT_29210105
HDAC19.07IC500.85nMCHEMBL_ACT_25701462
HDAC69Ki1nMCHEMBL_ACT_2167460
HDAC49IC501nMCHEMBL_ACT_25992099
HDAC59IC501nMCHEMBL_ACT_25992103
HDAC69IC501nMCHEMBL_ACT_25992107
HDAC99IC501nMCHEMBL_ACT_25992115
HDAC18.89Ki1.3nMCHEMBL_ACT_3390002
HDAC68.85IC501.4nMCHEMBL_ACT_16494699
HDAC38.85IC501.4nMCHEMBL_ACT_16494701
HDAC28.8Ki1.6nMCHEMBL_ACT_3390003
HDAC68.8Ki1.6nMCHEMBL_ACT_3390006
HDAC28.77IC501.7nMCHEMBL_ACT_10948230
HDAC38.77Ki1.7nMCHEMBL_ACT_25472465
HDAC18.72Ki1.9nMCHEMBL_ACT_25472460
HDAC68.7IC502nMCHEMBL_ACT_12680957
HDAC68.7IC502nMCHEMBL_ACT_13297555
HDAC38.7Ki2nMCHEMBL_ACT_2167450
HDAC18.7IC502nMCHEMBL_ACT_25472473
HDAC28.7IC502nMCHEMBL_ACT_25472475
HDAC38.7IC502nMCHEMBL_ACT_25472477
HDAC68.7IC502nMCHEMBL_ACT_25472480
HDAC28.7IC502nMCHEMBL_ACT_25992087
HDAC38.7IC502nMCHEMBL_ACT_25992091
HDAC78.7IC502nMCHEMBL_ACT_25992111
HDAC68.7IC502nMCHEMBL_ACT_27196025
HDAC68.57IC502.71nMCHEMBL_ACT_15731050

Target pathways

Aggregated over 9 target gene(s): HDAC10, HDAC11, HDAC2, HDAC3, HDAC6, HDAC8, HDAC9, HDAC1, HDAC5.

Top Reactome pathways

67 total, by targets touching each:

PathwayTargetsGenes
NOTCH1 Intracellular Domain Regulates Transcription9HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 PEST Domain Mutants9HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants9HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
Notch-HLH transcription pathway9HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)9HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
HDACs deacetylate histones5HDAC1, HDAC10, HDAC2, HDAC3, HDAC8
Regulation of PTEN gene transcription4HDAC1, HDAC2, HDAC3, HDAC5
p75NTR negatively regulates cell cycle via SC13HDAC1, HDAC2, HDAC3
Regulation of MECP2 expression and activity3HDAC1, HDAC2, HDAC3
STAT3 nuclear events downstream of ALK signaling3HDAC1, HDAC2, HDAC3
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression2HDAC1, HDAC2
NoRC negatively regulates rRNA expression2HDAC1, HDAC2
SUMOylation of chromatin organization proteins2HDAC1, HDAC2
Regulation of TP53 Activity through Acetylation2HDAC1, HDAC2
RNA Polymerase I Transcription Initiation2HDAC1, HDAC2
RUNX2 regulates osteoblast differentiation2HDAC3, HDAC6
MECP2 regulates neuronal receptors and channels2HDAC1, HDAC2
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes2HDAC1, HDAC2
Potential therapeutics for SARS2HDAC1, HDAC2
Negative Regulation of CDH1 Gene Transcription2HDAC1, HDAC2
Factors involved in megakaryocyte development and platelet production2HDAC1, HDAC2
Regulation of endogenous retroelements by KRAB-ZFP proteins2HDAC1, HDAC2
Transcriptional regulation of brown and beige adipocyte differentiation by EBF22HDAC1, HDAC2
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)2HDAC1, HDAC2
NuRD complex assembly2HDAC1, HDAC2
Interaction of NuRD complexes with transcription factors2HDAC1, HDAC2
Transcription of E2F targets under negative control by DREAM complex1HDAC1
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC11HDAC1
G0 and Early G11HDAC1
PPARA activates gene expression1HDAC3

Dominant GO biological processes

GO termTargets
chromatin organization9
negative regulation of transcription by RNA polymerase II7
negative regulation of DNA-templated transcription7
epigenetic regulation of gene expression4
positive regulation of transcription by RNA polymerase II4
negative regulation of gene expression, epigenetic4
response to xenobiotic stimulus3
heterochromatin formation3
circadian regulation of gene expression3
positive regulation of intracellular estrogen receptor signaling pathway3
negative regulation of apoptotic process3
rhythmic process3
protein deacetylation3
regulation of protein stability3
macroautophagy2

Indications & clinical

Indications

96 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
primary cutaneous T-cell non-Hodgkin lymphoma4MONDO:0000607EFO:0002913
neoplasm4MONDO:0005070EFO:0000616
T-cell non-Hodgkin lymphoma4MONDO:0015760MONDO:0015760
plasma cell myeloma3MONDO:0009693EFO:0001378
lymphoma3MONDO:0005062EFO:0000574
acute myeloid leukemia3MONDO:0018874EFO:0000222
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
mesothelioma3MONDO:0005065EFO:0000588
lung neoplasm3MONDO:0021117MONDO:0008903
HIV infectious disease2MONDO:0005109EFO:0000764
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
neuroblastoma2MONDO:0005072EFO:0000621
sarcoma2MONDO:0005089EFO:0000691
brain disorder2MONDO:0005560EFO:0005774
myelodysplastic syndrome2MONDO:0018881EFO:0000198
male breast carcinoma2MONDO:0005628EFO:0006861
renal cell carcinoma2MONDO:0005086EFO:0000681
mycosis fungoides2MONDO:0009691EFO:1001051
gliosarcoma2MONDO:0016681EFO:1001465
ovarian neoplasm2MONDO:0021068EFO:0003893
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
Hodgkins lymphoma2MONDO:0004952EFO:0000183
MALT lymphoma2MONDO:0007650EFO:0000191
acute lymphoblastic leukemia2MONDO:0004967EFO:0000220
clear cell renal carcinoma2MONDO:0005005EFO:0000349
glioblastoma2MONDO:0018177EFO:0000519
leukemia2MONDO:0005059EFO:0000565
prostate adenocarcinoma2MONDO:0005082EFO:0000673
anaplastic astrocytoma2MONDO:0016684EFO:0002499
breast neoplasm2MONDO:0021100EFO:0003869
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
Sezary syndrome2MONDO:0017844EFO:1000785
mantle cell lymphoma2MONDO:0018876EFO:1001469
soft tissue sarcoma2MONDO:0018078EFO:1001968
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
essential thrombocythemia2MONDO:0005029EFO:0000479
thyroid gland papillary carcinoma2MONDO:0005075EFO:0000641
acquired polycythemia vera2MONDO:0009891EFO:0002429
rectal cancer2MONDO:0006519EFO:1000657
ACTH-dependent Cushing syndrome2MONDO:0020528EFO:1001110
brain cancer2MONDO:0001657MONDO:0001657
ovarian cancer2MONDO:0008170MONDO:0008170
follicular lymphoma2MONDO:0018906MONDO:0018906
acute biphenotypic leukemia2MONDO:0020322MONDO:0019460
colonic neoplasm2MONDO:0005401MONDO:0021063
brain neoplasm2MONDO:0021211EFO:0003833
sickle cell disease2MONDO:0011382MONDO:0011382
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501
prostate carcinoma2MONDO:0005159EFO:0001663
uveal melanoma2MONDO:0006486EFO:1000616
colorectal neoplasm2MONDO:0005335MONDO:0005575
exocrine pancreatic carcinoma1MONDO:0005192EFO:0002618
melanoma1MONDO:0005105EFO:0000756
peripheral T-cell lymphoma, not otherwise specified1MONDO:0004964EFO:0000211
acute promyelocytic leukemia1MONDO:0012883EFO:0000224
Burkitt lymphoma1MONDO:0007243EFO:0000309
chronic myeloid leukemia1MONDO:0011996EFO:0000339
Crohn disease1MONDO:0005011EFO:0000384
diffuse large B-cell lymphoma1MONDO:0018905EFO:0000403
small cell lung carcinoma1MONDO:0008433EFO:0000702
anaplastic oligodendroglioma1MONDO:0016696EFO:0002501
medulloblastoma1MONDO:0007959EFO:0002939
verrucous carcinoma1MONDO:0006006EFO:0007535
juvenile myelomonocytic leukemia1MONDO:0011908EFO:1000309
Niemann-Pick disease1MONDO:0001982EFO:1001380
precursor T-cell acute lymphoblastic leukemia1MONDO:0020512EFO:1001830
hypopharyngeal carcinoma1MONDO:0005216EFO:0002938
diffuse intrinsic pontine glioma1MONDO:0006033EFO:1000026
gastric neoplasm1MONDO:0021085MONDO:0001056
anus neoplasm1MONDO:0003046MONDO:0001879
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
glioma1MONDO:0021042MONDO:0003268
oropharynx cancer1MONDO:0004608MONDO:0044926
laryngeal squamous cell carcinoma1MONDO:0005595EFO:0006352
skin neoplasm1MONDO:0002531EFO:0004198
Alzheimer disease1MONDO:0004975MONDO:0004975
lymphoid leukemia1MONDO:0005402EFO:0004289
head and neck squamous cell carcinoma1MONDO:0010150EFO:0000181
plasma cell neoplasm1MONDO:0004959EFO:0000200
salivary gland cancer1MONDO:0004669MONDO:0004669

14 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 256.

Phase distribution

PhaseTrials
PHASE1103
PHASE282
PHASE1/PHASE254
Not specified7
PHASE35
PHASE2/PHASE33
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03117751PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTotal Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT00128102PHASE3COMPLETEDSuberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
NCT00473889PHASE2/PHASE3TERMINATEDA Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
NCT00773747PHASE3COMPLETEDStudy of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
NCT01236560PHASE2/PHASE3COMPLETEDVorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
NCT01386398PHASE3WITHDRAWNVorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
NCT01728805PHASE3COMPLETEDStudy of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
NCT01802333PHASE3COMPLETEDCytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
NCT00392353PHASE1/PHASE2ACTIVE_NOT_RECRUITINGVorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
NCT00616967PHASE2ACTIVE_NOT_RECRUITINGCarboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
NCT00972478PHASE1/PHASE2ACTIVE_NOT_RECRUITINGVorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT01297764PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01522976PHASE2ACTIVE_NOT_RECRUITINGAzacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT01587352PHASE2ACTIVE_NOT_RECRUITINGVorinostat in Treating Patients With Metastatic Melanoma of the Eye
NCT02553460PHASE1/PHASE2ACTIVE_NOT_RECRUITINGTotal Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
NCT02559778PHASE2RECRUITINGPediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02638090PHASE1/PHASE2ACTIVE_NOT_RECRUITINGPembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT03167437PHASE1/PHASE2RECRUITINGAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
NCT03842696PHASE1/PHASE2ACTIVE_NOT_RECRUITINGVorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT05848687PHASE1/PHASE2RECRUITINGTINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
NCT06145633PHASE2RECRUITINGVorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
NCT06995521PHASE2NOT_YET_RECRUITINGVorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population
NCT07261241PHASE2NOT_YET_RECRUITINGNANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
NCT00121225PHASE2COMPLETEDVorinostat in Treating Patients With Metastatic or Unresectable Melanoma
NCT00126451PHASE2TERMINATEDA Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
NCT00132002PHASE2TERMINATEDSuberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
NCT00132028PHASE2COMPLETEDVorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin’s Lymphoma
NCT00132067PHASE2COMPLETEDVorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00134043PHASE2COMPLETEDSuberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
NCT00138203PHASE2COMPLETEDSuberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00238303PHASE2COMPLETEDVorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
NCT00251589PHASE1/PHASE2TERMINATEDA Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
NCT00253630PHASE2COMPLETEDVorinostat in Treating Patients With Low-Grade Non-Hodgkin’s Lymphoma
NCT00258349PHASE1/PHASE2COMPLETEDVorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
NCT00262834PHASE2COMPLETEDVorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
NCT00278395PHASE2COMPLETEDVorinostat in Treating Patients With Kidney Cancer
NCT00305773PHASE2COMPLETEDVorinostat in Treating Patients With Acute Myeloid Leukemia
NCT00324740PHASE1/PHASE2TERMINATEDVorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
NCT00324870PHASE1/PHASE2COMPLETEDVorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00330161PHASE2COMPLETEDVorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

Clinical evidence (CIViC)

Variant × indication × effect (8 predictive associations from 8 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
HDAC9 OverexpressionBreast CancerResistancePanobinostat + Trichostatin A + VorinostatCIViC BEID9230
BRD4::NUTM1 FusionNUT Midline CarcinomaSensitivity/ResponseVorinostatCIViC CEID12100
TP53 R175H OR TP53 H193RSarcomaSensitivity/ResponsePazopanib + VorinostatCIViC CEID7540
TP53 R273C OR TP53 G245S OR TP53 R213*Colorectal CancerSensitivity/ResponsePazopanib + VorinostatCIViC CEID12732
BAP1 MutationUveal MelanomaSensitivity/ResponseTrichostatin A + Vorinostat + Panobinostat + Valproic AcidCIViC DEID1234
HDAC6 OverexpressionEsophageal CancerSensitivity/ResponsePanobinostat + Trichostatin A + VorinostatCIViC DEID9856
RAD23B EXPRESSIONSarcomaSensitivity/ResponseVorinostatCIViC DEID1597
BAP1 LossMalignant MesotheliomaSensitivity/ResponseMocetinostat + VorinostatCIViC EEID1235

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

95 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
BELINOSTATChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
CELECOXIBChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
GIVINOSTATChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
PANOBINOSTATChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
PHENYLBUTANOIC ACIDChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
ROMIDEPSINChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
SODIUM PHENYLBUTYRATEChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
ABEXINOSTATChEMBLPhase 3HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
CAFFEIC ACIDChEMBLPhase 3HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
CURCUMINChEMBLPhase 3HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
ENTINOSTATChEMBLPhase 3HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
PRACINOSTATChEMBLPhase 3HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
TACEDINALINEChEMBLPhase 3HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
TUCIDINOSTATChEMBLPhase 3HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
AR-42ChEMBLPhase 2HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
CHLOROGENIC ACIDChEMBLPhase 2HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
DACINOSTATChEMBLPhase 2HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
FIMEPINOSTATChEMBLPhase 2HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
NANATINOSTATChEMBLPhase 2HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
QUISINOSTATChEMBLPhase 2HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
PazopanibPubChemApprovedHDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
BENDAMUSTINEChEMBLPhase 4 (approved)HDAC1, HDAC10, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8
RICOLINOSTATChEMBLPhase 2HDAC1, HDAC10, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8
DOMATINOSTATChEMBLPhase 2HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC9
MOCETINOSTATChEMBLPhase 2HDAC1, HDAC11, HDAC2, HDAC3, HDAC6, HDAC8
TINOSTAMUSTINEChEMBLPhase 2HDAC1, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8
BORTEZOMIBChEMBLPhase 4 (approved)HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
CITARINOSTATChEMBLPhase 2HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
EBSELENChEMBLPhase 3HDAC2, HDAC5, HDAC6, HDAC9
BUTYRIC ACIDChEMBLPhase 2HDAC1, HDAC2, HDAC3, HDAC8
SODIUM BUTYRATEChEMBLPhase 2HDAC1, HDAC2, HDAC3, HDAC8
.gamma.-aminobutyric acidPubChemApprovedHDAC10, HDAC11, HDAC5, HDAC9
acetylcysteinePubChemApprovedHDAC10, HDAC11, HDAC5, HDAC9
GefitinibPubChemApprovedHDAC10, HDAC11, HDAC5, HDAC9
ATORVASTATINChEMBLPhase 4 (approved)HDAC1, HDAC2, HDAC6
DAUNORUBICINChEMBLPhase 4 (approved)HDAC1, HDAC6, HDAC8
LOVASTATINChEMBLPhase 4 (approved)HDAC1, HDAC2, HDAC6
BAICALEINChEMBLPhase 2HDAC1, HDAC6, HDAC8
CrizotinibPubChemApprovedHDAC1, HDAC2, HDAC6
BUFEXAMACChEMBLPhase 4 (approved)HDAC10, HDAC6
VALPROIC ACIDChEMBLPhase 4 (approved)HDAC1, HDAC2
MOLIBRESIBChEMBLPhase 2HDAC1, HDAC2
NICOXAMATChEMBLPhase 2HDAC1, HDAC6
RESMINOSTATChEMBLPhase 2HDAC1, HDAC6
IdelalisibPubChemApprovedHDAC1, HDAC6
ABAMETAPIRChEMBLPhase 4 (approved)HDAC6
ATALURENChEMBLPhase 4 (approved)HDAC6
AXITINIBChEMBLPhase 4 (approved)HDAC6
EVANS BLUE FREE ACIDChEMBLPhase 4 (approved)HDAC6
EXIFONEChEMBLPhase 4 (approved)HDAC1
FEBUXOSTATChEMBLPhase 4 (approved)HDAC6
FLUPHENAZINEChEMBLPhase 4 (approved)HDAC6
GENTIAN VIOLETChEMBLPhase 4 (approved)HDAC6
INDOPROFENChEMBLPhase 4 (approved)HDAC6
MARIBAVIRChEMBLPhase 4 (approved)HDAC6
MOMELOTINIBChEMBLPhase 4 (approved)HDAC1
MONOBENZONEChEMBLPhase 4 (approved)HDAC6
NITAZOXANIDEChEMBLPhase 4 (approved)HDAC6
PHENYL AMINOSALICYLATEChEMBLPhase 4 (approved)HDAC6
PIPERACETAZINEChEMBLPhase 4 (approved)HDAC6

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot